Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 471: What is the toxic effect of lidocaine?

A. Increased salivation
B. Mydriasis and diarrhea
C. Respiratory paralysis
D. Seizures (Correct Answer)

Explanation: **Explanation:** Lidocaine is an amide-linked local anesthetic that acts by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction. Its toxicity primarily involves the **Central Nervous System (CNS)** and the **Cardiovascular System (CVS)**. **Why Seizures are the correct answer:** Lidocaine toxicity follows a predictable progression. At low toxic doses, it may cause circumoral numbness, tinnitus, and a metallic taste. As plasma levels rise, lidocaine crosses the blood-brain barrier and selectively inhibits **inhibitory cortical neurons**. This leads to unopposed excitatory activity, manifesting as tremors, twitching, and ultimately **generalized tonic-clonic seizures**. At even higher concentrations, global CNS depression and coma may occur. **Analysis of Incorrect Options:** * **A & B (Salivation, Mydriasis, Diarrhea):** These are autonomic symptoms. Salivation and diarrhea are typically associated with cholinergic excess (e.g., organophosphate poisoning), while mydriasis is seen in sympathomimetic or anticholinergic toxicity. Lidocaine does not significantly interact with these pathways. * **C (Respiratory paralysis):** While severe lidocaine toxicity can eventually lead to respiratory arrest due to medullary depression, it is a terminal event. Seizures are the classic, hallmark sign of CNS toxicity that precedes respiratory failure. **High-Yield Clinical Pearls for NEET-PG:** * **Early signs:** Tinnitus and circumoral paresthesia are high-yield "warning signs." * **CVS Toxicity:** Lidocaine is "cardio-stable" compared to Bupivacaine, but in overdose, it can cause bradycardia, hypotension, and PR interval prolongation. * **Management:** The specific antidote for local anesthetic systemic toxicity (LAST) is **Intravenous Lipid Emulsion (ILE) 20%**. * **Metabolism:** Lidocaine is metabolized in the liver; hence, toxicity is more likely in patients with hepatic failure or reduced hepatic blood flow (e.g., CHF).

Question 472: Which of the following drugs causes oligospermia?

A. Leflunomide
B. D-Penicillamine
C. Methotrexate
D. Sulfasalazine (Correct Answer)

Explanation: **Explanation:** **Sulfasalazine** is a prodrug composed of 5-aminosalicylic acid (5-ASA) and sulfapyridine, linked by a diazo bond. While 5-ASA provides the therapeutic effect in inflammatory bowel disease (IBD), the **sulfapyridine moiety** is responsible for most of its systemic side effects, including **reversible oligospermia**. It affects sperm count, motility, and morphology. The mechanism is thought to involve oxidative stress and interference with folic acid metabolism in the testes. Crucially, this effect is **reversible** within 2–3 months of drug discontinuation. **Analysis of Incorrect Options:** * **Leflunomide:** An inhibitor of dihydroorotate dehydrogenase used in Rheumatoid Arthritis. While it is highly teratogenic (Category X), it is not typically associated with oligospermia. * **D-Penicillamine:** A chelating agent used in Wilson’s disease and formerly in RA. Its major toxicities include nephrotic syndrome, bone marrow suppression, and dermatological issues (e.g., elastosis perforans serpiginosa), but not male infertility. * **Methotrexate:** While high-dose methotrexate can temporarily suppress spermatogenesis due to its cytotoxic nature as a folate antagonist, it is not the classic "textbook" answer for drug-induced oligospermia in the context of DMARDs/IBD therapy compared to Sulfasalazine. **Clinical Pearls for NEET-PG:** * **Reversibility:** Always remember that Sulfasalazine-induced infertility is reversible; switching to **Mesalamine** (which lacks the sulfapyridine component) resolves the issue. * **Other drugs causing oligospermia:** Nitrofurantoin, Cimetidine, Spironolactone, and Cyclophosphamide (often irreversible). * **Mnemonic:** "S" for **S**ulfasalazine causes **S**perm suppression.

Question 473: Pralidoxime is ineffective in case of which poisoning?

A. Organophosphorous
B. Carbaryl (Correct Answer)
C. Both of the above
D. None of the above

Explanation: **Explanation:** The correct answer is **Carbaryl (Option B)**. To understand why, we must look at the mechanism of action of Oximes (like Pralidoxime) and the chemical nature of the enzyme inhibition. **1. Why Carbaryl is the correct answer:** Carbaryl is a **Carbamate** insecticide. Carbamates inhibit the enzyme Acetylcholinesterase (AChE) by "carbamylating" it. This bond is **spontaneously reversible** and, more importantly, the enzyme-carbamate complex does not undergo "aging." Pralidoxime is not only unnecessary because the enzyme recovers on its own, but it is actually **contraindicated**. Pralidoxime has weak anticholinesterase activity itself; in carbamate poisoning, it can further inhibit the enzyme, potentially worsening the toxicity. **2. Why the other options are incorrect:** * **Organophosphorous (OP) compounds:** These inhibit AChE by "phosphorylating" it. This bond is strong and can become permanent through a process called **"Aging."** Pralidoxime works as a "cholinesterase reactivator" by displacing the phosphate group before aging occurs. Therefore, it is highly effective and indicated in OP poisoning. * **Options C and D:** These are incorrect based on the distinct pharmacological response of OP vs. Carbamates to oximes. **Clinical Pearls for NEET-PG:** * **The Exception:** While oximes are generally avoided in carbamates, **Neostigmine and Physostigmine** are also carbamates, but they are drugs, not poisons. * **Aging:** Once an OP-enzyme complex "ages," oximes can no longer reactivate the enzyme. This is why Pralidoxime must be given early (ideally within 24–48 hours). * **Atropine:** It is the antidote of choice for **both** OP and Carbamate poisoning because it antagonizes the muscarinic effects, regardless of the enzyme status. * **Mnemonic:** "Oximes for Organophosphates, but NOT for Carbamates."

Question 474: Which one of the following is not a cause for hyperkalemia?

A. Digoxin (Correct Answer)
B. Potassium sparing diuretic
C. Renin angiotensin system blockers
D. Cyclosporine

Explanation: **Explanation:** The correct answer is **A. Digoxin**. While acute digoxin toxicity can cause hyperkalemia, therapeutic doses or standard clinical use of digoxin do not typically cause hyperkalemia as a primary side effect. In contrast, the other listed drugs are classic causes of elevated potassium levels. **Why the options are incorrect (Causes of Hyperkalemia):** * **Potassium-sparing diuretics (e.g., Spironolactone, Amiloride):** These drugs act on the distal tubule and collecting duct to inhibit sodium reabsorption and potassium secretion, directly leading to potassium retention. * **Renin-Angiotensin System (RAS) Blockers (e.g., ACE inhibitors, ARBs):** These agents decrease aldosterone levels. Since aldosterone is responsible for excreting potassium in the kidneys, its inhibition leads to hyperkalemia. * **Cyclosporine:** This calcineurin inhibitor causes hyperkalemia by suppressing aldosterone synthesis and inducing tubular resistance to aldosterone. **Clinical Pearls for NEET-PG:** * **Digoxin & Potassium Relationship:** 1. **Hypokalemia** predisposes a patient to **Digoxin toxicity** (because K+ and Digoxin compete for the same binding site on the Na+/K+ ATPase pump). 2. **Acute Digoxin Toxicity** causes **Hyperkalemia** (due to massive inhibition of the Na+/K+ pump, preventing K+ from entering cells). However, in the context of general drug side effects (as implied by the question), Digoxin is not classified as a "cause" of hyperkalemia like the others. * **Other high-yield causes of hyperkalemia:** NSAIDs, Heparin, Succinylcholine, and Beta-blockers. * **Management:** For severe hyperkalemia, use Calcium gluconate (cardioprotection), followed by Insulin + Glucose or Salbutamol (to shift K+ intracellularly).

Question 475: Lead poisoning causes all the following except:

A. Saturnine gout
B. Sideroblastic anemia
C. Basophilic stippling
D. Macrocytic anemia (Correct Answer)

Explanation: **Explanation:** Lead poisoning (Plumbism) primarily affects the hematological, renal, and neurological systems. The correct answer is **Macrocytic anemia** because lead poisoning characteristically causes **Microcytic Hypochromic Anemia**, not macrocytic. **1. Why Macrocytic Anemia is the correct (Except) option:** Lead inhibits two key enzymes in the heme synthesis pathway: **δ-aminolevulinic acid dehydratase (ALAD)** and **Ferrochelatase**. This inhibition prevents the incorporation of iron into protoporphyrin, leading to decreased hemoglobin synthesis and the production of small, pale red blood cells (Microcytic Hypochromic Anemia). **2. Analysis of Incorrect Options:** * **Basophilic Stippling:** Lead inhibits the enzyme **1,5-pyrimidine nucleotidase**, which normally degrades ribosomal RNA. The persistence of undegraded RNA fragments in RBCs appears as blue granules (stippling) on a peripheral smear. * **Sideroblastic Anemia:** Due to the failure of iron incorporation into heme, iron accumulates within the mitochondria of erythroid precursors, forming "ringed sideroblasts" in the bone marrow. * **Saturnine Gout:** Lead causes proximal tubular damage in the kidneys, which decreases the excretion of uric acid. This lead-induced hyperuricemia results in a secondary form of gout known as Saturnine gout. **High-Yield Clinical Pearls for NEET-PG:** * **Burton’s Line:** A characteristic bluish-purple line on the gingival margins (gums). * **Wrist Drop/Foot Drop:** Due to peripheral demyelination (radial and peroneal nerve palsy). * **Diagnosis:** Best initial screening is **Whole Blood Lead Levels**. * **Treatment (Chelation):** * Oral: **Succimer** (DMSA) - preferred in children. * Parenteral: **Dimercaprol** (BAL) and **Calcium EDTA**.

Question 476: What is the drug of choice for substitution therapy in morphine dependence?

A. Methadone (Correct Answer)
B. Clonidine
C. Naloxone
D. Nalmefene

Explanation: ### Explanation **Correct Option: A. Methadone** Methadone is a long-acting **mu-opioid receptor full agonist**. In morphine or heroin dependence, it is the drug of choice for substitution therapy because of its unique pharmacokinetic profile: * **Long Half-life (24–36 hours):** It prevents the rapid "high" and subsequent "crash" associated with short-acting opioids like morphine. * **Oral Bioavailability:** It can be administered orally, eliminating the need for injections. * **Cross-Tolerance:** It maintains a steady state in the blood, suppressing withdrawal symptoms and reducing drug-seeking behavior (craving) through cross-tolerance. **Analysis of Incorrect Options:** * **B. Clonidine:** It is an alpha-2 agonist used to treat the **autonomic symptoms** of opioid withdrawal (tachycardia, hypertension, sweating). It is *not* a substitution therapy as it does not act on opioid receptors. * **C. Naloxone:** A short-acting opioid **antagonist** used primarily for the emergency reversal of acute opioid overdose. Giving it to a dependent patient would precipitate immediate, severe withdrawal. * **D. Nalmefene:** A long-acting opioid antagonist (similar to Naltrexone) used in the management of alcohol dependence and occasionally for reversing opioid effects, but never for substitution therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Buprenorphine:** A partial mu-agonist and kappa-antagonist. It is also used for substitution therapy and has a lower risk of overdose due to its "ceiling effect" on respiratory depression. * **Naltrexone:** Used for **maintenance of abstinence** (relapse prevention) *after* detoxification is complete. * **Substitution vs. Antidote:** Always distinguish between substitution (Methadone/Buprenorphine), symptomatic relief (Clonidine), and acute reversal (Naloxone).

Question 477: What is the antidote for copper poisoning?

A. D-penicillamine
B. Potassium ferrocyanide (Correct Answer)
C. BAL
D. Desferrioxamine

Explanation: **Explanation:** The correct answer is **Potassium ferrocyanide**. In cases of acute copper poisoning (often due to ingestion of copper sulfate/blue vitriol), **Potassium ferrocyanide** is considered the specific chemical antidote. When administered, it reacts with copper sulfate in the stomach to form **cupric ferrocyanide**, which is an insoluble, non-toxic precipitate. This prevents the systemic absorption of copper, effectively neutralizing the poison locally. **Analysis of Options:** * **A. D-penicillamine:** While this is the drug of choice for **chronic copper toxicity** (Wilson’s Disease) and can be used as a systemic chelator in acute poisoning after stabilization, it is not the specific neutralizing agent for acute ingestion in the gastrointestinal tract. * **C. BAL (British Anti-Lewisite/Dimercaprol):** This is a chelating agent primarily used for heavy metals like **Arsenic, Mercury, and Lead**. It is generally avoided in copper poisoning unless other options are unavailable. * **D. Desferrioxamine:** This is the specific chelating agent for **Iron toxicity**. **High-Yield Clinical Pearls for NEET-PG:** * **Acute Copper Poisoning:** Characterized by a metallic taste, blue-green vomitus (due to copper sulfate), and "Green Hair" in chronic exposure. * **Wilson’s Disease:** A genetic disorder of copper metabolism where **D-penicillamine** or **Trientine** are used for long-term management. * **Zinc:** Oral zinc is used in Wilson’s disease to block intestinal absorption of copper by inducing metallothionein. * **Universal Antidote:** Consists of Charcoal, Magnesium oxide, and Tannic acid (though largely replaced by Activated Charcoal).

Question 478: What is a known complication of cyclosporine therapy?

A. Hypertension (Correct Answer)
B. Pulmonary fibrosis
C. Corneal deposits
D. Nephrotoxicity

Explanation: **Explanation:** **Cyclosporine** is a potent calcineurin inhibitor used primarily to prevent organ transplant rejection and treat autoimmune conditions. **Why Hypertension is the Correct Answer:** Hypertension is one of the most common and clinically significant side effects of cyclosporine, occurring in approximately 50% of renal transplant recipients [1]. The underlying mechanism involves **systemic vasoconstriction** caused by an increase in endothelin production, a decrease in nitric oxide (NO) release, and activation of the renin-angiotensin-aldosterone system (RAAS). This leads to increased peripheral vascular resistance and sodium retention [2]. **Analysis of Incorrect Options:** * **B. Pulmonary fibrosis:** This is a classic side effect of **Bleomycin**, Busulfan, and Amiodarone, but not cyclosporine. * **C. Corneal deposits:** These are associated with drugs like **Amiodarone** and **Chloroquine** (vortex keratopathy). * **D. Nephrotoxicity:** While cyclosporine is notoriously nephrotoxic (causing both acute and chronic renal impairment), in the context of many standardized exams, if both are listed, **Hypertension** is often highlighted as a specific hemodynamic complication, though both are technically correct [1], [2]. *Note: In many NEET-PG style questions, if "All of the above" is not an option, Hypertension is frequently the sought-after "clinical" complication.* **High-Yield Clinical Pearls for NEET-PG:** * **The "G" Side Effects:** Remember the mnemonic for Cyclosporine: **G**ingival hyperplasia, **G**lucose intolerance (Diabetes), and **G**out (Hyperuricemia) [1]. * **Other Side Effects:** Nephrotoxicity (most common dose-limiting toxicity), Hirsutism, Tremors, and Hyperkalemia [1]. * **Drug Interactions:** Cyclosporine is metabolized by **CYP3A4**; therefore, enzyme inhibitors (e.g., Ketoconazole, Erythromycin) increase its toxicity. * **Tacrolimus vs. Cyclosporine:** Tacrolimus is more potent and does *not* cause hirsutism or gingival hyperplasia, but has a higher risk of causing New-Onset Diabetes After Transplantation (NODAT).

Question 479: Which of the following is a serious adverse effect seen with Zoledronate?

A. Acute renal failure (Correct Answer)
B. Ventricular fibrillation
C. Peptic ulcer
D. Anterior uveitis

Explanation: **Explanation:** **Zoledronate (Zoledronic acid)** is a potent, intravenous third-generation nitrogen-containing bisphosphonate used in the management of osteoporosis, Paget’s disease, and skeletal complications of malignancy. **Why Acute Renal Failure is correct:** The most serious systemic adverse effect of intravenous zoledronate is **nephrotoxicity**, specifically **Acute Renal Failure (ARF)** or acute tubular necrosis. This occurs because bisphosphonates are excreted unchanged by the kidneys. Rapid intravenous infusion can lead to high peak plasma concentrations, causing the drug to precipitate with calcium in the renal tubules or exert direct toxic effects on tubular cells. To mitigate this risk, it must be administered over at least 15 minutes with adequate patient hydration. **Analysis of Incorrect Options:** * **B. Ventricular fibrillation:** While intravenous bisphosphonates have been associated with atrial fibrillation in some studies, they do not typically cause ventricular fibrillation. * **C. Peptic ulcer:** This is a classic side effect of **oral bisphosphonates** (like Alendronate) due to direct esophageal and gastric mucosal irritation. Since Zoledronate is given IV, it bypasses the GI tract and does not cause peptic ulcers. * **D. Anterior uveitis:** While bisphosphonates can cause ocular inflammation (like scleritis or uveitis), it is considered a rare idiosyncratic reaction rather than a common "serious" systemic complication like renal failure. **NEET-PG High-Yield Pearls:** * **Osteonecrosis of the Jaw (ONJ):** A high-yield "dreaded" complication of long-term, high-dose bisphosphonate therapy, especially in cancer patients. * **Flu-like Syndrome:** The most common acute side effect of Zoledronate (fever, myalgia) occurring within 24–72 hours of infusion. * **Contraindication:** Zoledronate is generally contraindicated if **Creatinine Clearance (CrCl) is <35 mL/min**. * **Atypical Subtrochanteric Fractures:** Associated with long-term use due to over-suppression of bone turnover.

Question 480: All of the following agents are used in the management of obesity EXCEPT?

A. Orlistat
B. Sibutramine
C. Olestra
D. Neuropeptide Y analogues (Correct Answer)

Explanation: **Explanation:** The management of obesity involves drugs that either reduce nutrient absorption, suppress appetite, or increase satiety. [1] **1. Why Neuropeptide Y (NPY) analogues are the correct answer:** Neuropeptide Y is one of the most potent **orexigenic (appetite-stimulating)** peptides found in the brain (specifically the hypothalamus). It increases food intake and promotes fat storage. Therefore, an **analogue** (agonist) of NPY would cause weight gain, not loss. To treat obesity, one would need NPY **antagonists** (specifically Y1 and Y5 receptor antagonists), which are currently under investigation. **2. Analysis of incorrect options:** * **Orlistat:** A potent, reversible inhibitor of **gastric and pancreatic lipases**. It prevents the hydrolysis of dietary fats (triglycerides) into absorbable free fatty acids, reducing fat absorption by approximately 30%. * **Sibutramine:** A combined **Norepinephrine and Serotonin Reuptake Inhibitor (NSRI)**. It promotes satiety and increases metabolic rate. *Note: It has been withdrawn in many countries due to increased cardiovascular risks (SCOUT trial), but remains a classic textbook example of an anti-obesity drug. [1]* * **Olestra:** A **non-absorbable fat substitute** (sucrose polyester) used in food preparation. It mimics the texture of fat but cannot be hydrolyzed by digestive enzymes, thus contributing zero calories. **High-Yield Clinical Pearls for NEET-PG:** * **Liraglutide/Semaglutide:** GLP-1 analogues are currently the "gold standard" for pharmacological weight loss. [1], [2] * **Lorcaserin:** A selective 5-HT$_{2C}$ receptor agonist (withdrawn recently due to cancer risk). * **Qsymia:** A fixed-dose combination of Phentermine (appetite suppressant) and Topiramate (antiepileptic with weight loss side effects). * **Side effect of Orlistat:** Steatorrhea (oily spotting) and deficiency of fat-soluble vitamins (A, D, E, K).

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free